BIOTHERIS

BIOTHERIS - publications majeures

• Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. J Immunother Cancer. 2024 Apr 18;12(4):e008378. doi: 10.1136/jitc-2023-008378. PMID: 38641350; PMCID: PMC11029323.
• Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors. J Immunother Cancer. 2025 Feb 20;13(2):e010511. doi: 10.1136/jitc-2024-010511. PMID: 39979069; PMCID: PMC11842995.
• Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115. Eur J Cancer. 2024 Aug;207:114120. doi: 10.1016/j.ejca.2024.114120. Epub 2024 May 15. PMID: 38870745.
• Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301). J Clin Oncol. 2025 May 20;43(15):1800-1809. doi: 10.1200/JCO.24.00727. Epub 2025 Mar 6. PMID: 40048691.
• Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice. J Immunother Cancer. 2023 Nov;11(11):e007433. doi: 10.1136/jitc-2023-007433. PMID: 37949616; PMCID: PMC10649793.
• Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022 Aug;3(8):911-926. doi: 10.1038/s43018-022-00418-6. Epub 2022 Aug 23. PMID: 35999309.
• Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies. J Immunother Cancer. 2020 Jun;8(1):e000579. doi: 10.1136/jitc-2020-000579. PMID: 32571995; PMCID: PMC7307549.
• Interventional Radiology for Local Immunotherapy in Oncology. Clin Cancer Res. 2021 May 15;27(10):2698-2705. doi: 10.1158/1078-0432.CCR-19-4073. Epub 2021 Jan 8. PMID: 33419781.
• Intratumoral Immunotherapy: From Trial Design to Clinical Practice. Clin Cancer Res. 2021 Feb 1;27(3):665-679. doi: 10.1158/1078-0432.CCR-20-0473. Epub 2020 Sep 17. PMID: 32943460.
• Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). Ann Oncol. 2018 Nov 1;29(11):2163-2174. doi: 10.1093/annonc/mdy423. PMID: 30295695; PMCID: PMC6290929.
• Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. 2017 Dec 1;28(suppl_12):xii33-xii43. doi: 10.1093/annonc/mdx683. PMID: 29253115.